Rituximab Noninferior to Ocrelizumab in Relapsing MS

Rituximab is noninferior to ocrelizumab in suppressing disease activity in newly diagnosed multiple sclerosis, with a similar incidence of adverse events, a new trial shows.
Medscape Medical News

source https://www.medscape.com/viewarticle/rituximab-noninferior-ocrelizumab-relapsing-ms-2026a1000nij?src=rss

Comments

Popular posts from this blog

Student Nurses Who Refuse Vaccination Struggle to Complete Degrees